Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer

References

Page 1

	Year	Citations
Global cancer statistics Ahmedin Jemal, Freddie Bray CA A Cancer Journal for Clinicians	2011	55K
Global cancer statistics, 2012 Lindsey A. Torre, Freddie Bray, Rebecca L. Siegel, CA A Cancer Journal for Clinicians	2015	27.2K
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, New England Journal of Medicine	2016	9.8K
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer H. Borghaei, L. Paz-Ares, Leora Horn, New England Journal of Medicine	2015	9.3K
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer Julie R. Brahmer, Karen L. Reckamp, Paul Baas, New England Journal of Medicine	2015	8.4K
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, The Lancet Non-small-cell Lung CancerMedicineMetronomic TherapyClinical TrialsPathology	2016	4.7K
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity Sydney Gordon, Roy L. Maute, Ben W. Dulken, Nature InflammationCancer ImmunosurveillancePd-1 ExpressionImmunologyTumor Immunity	2017	2.2K
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs Mark G. Kris, Bruce E. Johnson, Lynne D. Berry, JAMA	2014	1.7K
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy Yuhui Huang, Jian‐Ping Yuan, Elda Righi, Proceedings of the National Academy of Sciences	2012	1K
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer Triparna Sen, B. Leticia Rodriguez, Limo Chen, Cancer Discovery	2019	841

Page 1